Page 148 - CW E-Magazine (3-6-2025)

Pharmaceuticals

REDUCING EMISSIONS

Lupin and Honeywell join hands to use HFO

technology in inhalers

Lupin has announced plans to pressurised metered-dose inhalers
use Honeywell’s Solstice Air (HFO- (pMDIs).
1234ze cGMP) propellant to trans-
form respiratory care through the Solstice Air isa said to offer an
development of next-generation alternative to traditional hydrofl uoro-
inhalers. carbon (HFC)-based propellants, helping
to reduce greenhouse gas emissions by
Designed for patients with asthma up to 99.9%.1 “By integrating Solstice
and chronic obstructive pulmonary in helping to reduce carbon emissions. Air in our products, we are not only
disease (COPD), Solstice Air has the Lupin intends to become the fi rst enhancing patient care, but we are also
potential to prevent the release of high pharmaceutical company in India to use signifi cantly reducing environmental
global warming potential (GWP) mole- Honeywell’s Solstice Air product at impact,” said Ms. Vinita Gupta, CEO,
cules, marking a major step forward scale as a next-generation propellant in Lupin.

Sun Pharma to invest $25-mn in US biopharma

company

Sun Pharmaceutical Industries has approved in India and marketed through already has an exclusive licence to
entered into an agreement with US partners under brands, Tyvalzi market Sovateltide in certain emerging
biopharmaceutical company, Pharmazz, (Sovateltide) and Lyfaquin (Centhaquine), markets.
to invest up to $25-mn. The investment, besides being developed for the US
post approvals and other procedures, and other markets, Sun informed. The The investment, at $5.88925 per
will peg Sun Pharma’s investment in company’s consolidated turnover for share in cash, triggers conversion of
the company at 22.7 percent. FY 2023-24 was $3-mn. investment under SAFE (Simple Agree-
ment for Future Equity) at 20 percent
The company is developing two Explaining its investment, Sun discount or $4.7114 per share. Post the
drug candidates, Sovateltide for the Pharma said, it would have an option current investment and SAFE conver-
treatment of acute cerebral ischemic to negotiate licensing of Sovateltide sion, Sun’s stake in Pharmazz would be
stroke, and Centhaquine for hypo- for marketing and distribution in cer- 22.7 percent on a fully dilutive basis,
volemic shock. Both products are tain developed market countries. Sun it said.

Aurobindo Pharma’s Q4 net profi t drops marginally

Hyderabad-based Aurobindo Pharma For the full year FY25, steadily towards the
has posted a marginal decrease in Aurobindo posted a 9.9 $1-billion revenue
its net profi t at Rs. 903-crore in the percent increase in net milestone. Backed
fourth quarter ended March 31, 2025, profi t to Rs. 3,484-crore by our ongoing capa-
compared with Rs. 907-crore in the (Rs. 3,169-crore) on 9.4 city enhancements
corresponding quarter of the previous percent growth in reve- we remain firmly
fi nancial year. The total revenue of the nue to Rs. 31,724-crore positioned to sustain
company increased 10.6 percent to (Rs. 29,002-crore). our trajectory,” said
Rs. 8,332-crore in the quarter under Mr. K. Nithyananda
review (from Rs. 7,580-crore in the “Our European operations continue Reddy, Vice-Cha irman and Managing
same year-ago period). to perform exceptionally well, moving Director, Aurobindo Pharma.

148 Chemical Weekly June 3, 2025

Contents Index to Advertisers Index to Products Advertised